#### **HANTSON LUDWIG**

Form 4

March 04, 2019

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB

3235-0287 Number:

January 31, Expires: 2005

0.5

**OMB APPROVAL** 

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* **HANTSON LUDWIG** 

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to

Issuer

below)

Symbol

ALEXION PHARMACEUTICALS,

(Check all applicable)

CEO

below)

INC. [ALXN]

(Last) (First) (Middle) 3. Date of Earliest Transaction

X\_ Director 10% Owner X\_ Officer (give title Other (specify

(Month/Day/Year) 02/28/2019

C/O ALEXION PHARMACEUTICALS, INC., 121

(Street)

SEAPORT BLVD

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

BOSTON, MA 02210

(City)

(State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if (Instr. 3) (Month/Day/Year)

4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)

5. Amount of 7. Nature of Securities Ownership Indirect Beneficially Form: Direct Beneficial Owned (D) or Ownership **Following** Indirect (I) (Instr. 4)

(Instr. 4)

Reported (A)

Transaction(s) (Instr. 3 and 4) Code V Amount (D) Price

Common

Stock, par 4,043 value 02/28/2019 F (1) \$.0001 per

\$ D 132.92 133,638 D (2)

share

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control

### Edgar Filing: HANTSON LUDWIG - Form 4

#### number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of | 2.          | 3. Transaction Date | 3A. Deemed         | 4.         | 5.         | 6. Date Exerc | cisable and | 7. Title     | e and             | 8. Price of | 9. Nu  |
|-------------|-------------|---------------------|--------------------|------------|------------|---------------|-------------|--------------|-------------------|-------------|--------|
| Derivative  | Conversion  | (Month/Day/Year)    | Execution Date, if | Transacti  | onNumber   | Expiration D  | ate         | Amour        | nt of             | Derivative  | Deriv  |
| Security    | or Exercise |                     | any                | Code       | of         | (Month/Day/   | Year)       | Underl       | ying              | Security    | Secui  |
| (Instr. 3)  | Price of    |                     | (Month/Day/Year)   | (Instr. 8) | Derivative | e             |             | Securit      | ties              | (Instr. 5)  | Bene   |
|             | Derivative  |                     |                    |            | Securities |               |             | (Instr.      | 3 and 4)          |             | Owne   |
|             | Security    |                     |                    |            | Acquired   | Acquired      |             |              |                   |             | Follo  |
|             |             |                     |                    |            | (A) or     |               |             |              |                   |             | Repo   |
|             |             |                     |                    |            | Disposed   |               |             |              |                   |             | Trans  |
|             |             |                     |                    |            | of (D)     |               |             |              |                   |             | (Instr |
|             |             |                     |                    |            | (Instr. 3, |               |             |              |                   |             |        |
|             |             |                     |                    |            | 4, and 5)  |               |             |              |                   |             |        |
|             |             |                     |                    |            |            |               |             |              | Amount            |             |        |
|             |             |                     |                    |            |            |               |             |              | Amount            |             |        |
|             |             |                     |                    |            |            | Date          | Expiration  |              | or<br>Name la sur |             |        |
|             |             |                     |                    |            |            | Exercisable   | Date        | Title Number |                   |             |        |
|             |             |                     |                    | C 1 W      | (A) (D)    |               |             |              | of                |             |        |
|             |             |                     |                    | Code V     | (A) (D)    |               |             |              | Shares            |             |        |

## **Reporting Owners**

| Reporting Owner Name / Address  | Relationships |           |         |       |  |  |
|---|---------------|-----------|---------|-------|--|--|
|   | Director      | 10% Owner | Officer | Other |  |  |
| HANTSON LUDWIG<br>C/O ALEXION PHARMACEUTICALS, INC.<br>121 SEAPORT BLVD<br>BOSTON, MA 02210 | X             |           | CEO     |       |  |  |

## **Signatures**

/s/ Douglas Barry, Attorney-in-Fact for Ludwig
Hantson
03/04/2019

\*\*Signature of Reporting Person Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$132.90- \$134.70. The price reported in (2) this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2